октреотид
Also known as SMS995, octrotide
Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 and binds predominantly to the somatostatin receptors SSTR2 and SSTR5.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458287873
- Drug.image
- Octreotide.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Octreotride PDB-6vc1.png
- Drug.image_class2
- bg-transparent
- Drug.caption
- 3D structure of octreotide.
- Drug.tradename
- Sandostatin, Bynfezia Pen, Mycapssa, others
- Drug.MedlinePlus
- a693049
- Drug.DailyMedID
- Octreotide
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
Article · Русский
Октреотид (торговое название Сандостатин и др.) — октапептид, который имитирует естественный соматостатин фармакологически, хотя он также является более мощным ингибитором гормона роста, глюкагона и инсулина, чем естественный гормон. Он был впервые синтезирован в 1979 году химиком Вилфридом Бауэром.
Abstract from DBpedia / Wikipedia · CC BY-SA
Connections
Categories
Chemical articles with multiple CAS registry numbersChemical articles with multiple PubChem CIDsChemicals using indexlabelsCyclic peptidesDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by NovartisDrugs developed by Sun PharmaDrugs with non-standard legal statusMultiple chemicals in Infobox drugOctapeptides